Virbac SA (VIRB.PA)

VIRB.PA on Paris Stock Exchange

197.95EUR
11:35am EST
Change (% chg)

€-1.25 (-0.63%)
Prev Close
€199.20
Open
€198.85
Day's High
€199.35
Day's Low
€193.75
Volume
9,366
Avg. Vol
5,269
52-wk High
€199.35
52-wk Low
€139.90

VIRB.PA

Chart for VIRB.PA

About

Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus... (more)

Overall

Beta: 0.28
Market Cap(Mil.): €1,684.83
Shares Outstanding(Mil.): 8.46
Dividend: 1.90
Yield (%): 0.95

Financials

  VIRB.PA Industry Sector
P/E (TTM): 30.12 39.77 40.41
EPS (TTM): 6.61 -- --
ROI: 10.21 19.02 18.28
ROE: 15.28 19.82 19.19
Search Stocks

BRIEF-Virbac FY revenue grows to 773.2 million euros

* Consolidated revenue in Q4 reached 204.2 million euros ($236.9 million), a 13 percent growth compared to the same period of last year

15 Jan 2015

BRIEF-Virbac closes Sentinel brands family acquisition Eli Lilly

* Announces closing of Sentinel brands family acquisition in United States from Eli Lilly

05 Jan 2015

Deals of the day- Mergers and acquisitions

(Adds American Apparel, Goldman Sachs, Procter & Gamble and others)

22 Dec 2014

Lilly must divest Sentinel products after FTC nod on Novartis deal

WASHINGTON - Eli Lilly and Co has won approval to buy Novartis AG's animal health unit on condition that it divests its Sentinel line of products for treating heartworm in dogs, the Federal Trade Commission said on Monday.

22 Dec 2014

Lilly must divest Sentinel products after FTC nod on Novartis deal

WASHINGTON - Eli Lilly and Co has won approval to buy Novartis AG's animal health unit on condition that it divests its Sentinel line of products for treating heartworm in dogs, the Federal Trade Commission said on Monday.

22 Dec 2014

BRIEF-Virbac sees FY organic growth of about 4 to 6 pct

* Says operating profitability for the full year should, as announced, stay close to the level achieved in 2013 Source text: http://bit.ly/1xz4JZJ Further company coverage: (Gdynia Newsroom: +48 58 698 39 20)

14 Nov 2014

BRIEF-Virbac to acquire United States veterinary assets from Eli Lilly

* Agrees to acquire veterinary assets from Eli Lilly in United States

27 Oct 2014

BRIEF-Virbac reports Q3 sales of 202.7 mln euros, up from 183.4 mln euros last year

* Q3 consolidated net sales 202.7 million euros versus 183.4 million euros last year Source text for Eikon: Further company coverage:

16 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks